We are live on
!
Find out more
EC
Euclidean Capital Portfolio holdings
AUM
$392M
1-Year Est. Return
31.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.51%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$206M
AUM Growth
-$102M
(-33%)
Cap. Flow
-$96.1M
Cap. Flow
% of AUM
-46.71%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
16
New
2
Increased
1
Reduced
4
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenaya Therapeutics
TNYA
|
+$19.7M |
| 2 |
Surrozen
SRZN
|
+$7.53M |
| 3 |
Pinduoduo
PDD
|
+$239K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PMV Pharmaceuticals
PMVP
|
+$36.4M |
| 2 |
Denali Therapeutics
DNLI
|
+$25.4M |
| 3 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$18.7M |
| 4 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$14.6M |
| 5 |
Snowflake
SNOW
|
+$11.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.48% |
| 2 | Financials | 1.97% |
| 3 | Consumer Discretionary | 0.54% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PMV Pharmaceuticals
PMVP
$59.2M
| $82.5M | 40.12% |
2,769,813
-1,138,864
| -29% | -$36.4M |
|
2
Alector
ALEC
$168M
| $22.4M | 10.88% |
980,894
| – | – |
|
|
RAPT
3
DELISTED
RAPT Therapeutics
RAPT
| $19.7M | 9.59% |
79,397
-12,578
| -14% | -$3.33M |
|
|
4
Tenaya Therapeutics
TNYA
$161M
| $18.9M | 9.19% |
+915,705
| New | +$19.7M |
|
5
Foghorn Therapeutics
FHTX
$266M
| $17.6M | 8.54% |
1,261,261
| – | – |
|
|
NGM
6
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $17.5M | 8.5% |
832,274
-661,075
| -44% | -$14.6M |
|
7
Oric Pharmaceuticals
ORIC
$1.15B
| $16.3M | 7.9% |
777,193
-219,541
| -22% | -$4.45M |
|
|
8
Surrozen
SRZN
$258M
| $5.68M | 2.76% |
+53,531
| New | +$7.53M |
|
9
First Financial Bancorp
FFBC
$3.55B
| $4.06M | 1.97% |
173,576
| – | – |
|
|
10
Pinduoduo
PDD
$126B
| $1.11M | 0.54% |
12,262
+2,456
| +25% | +$239K |
|
11
Beam Therapeutics
BEAM
$2.63B
| – | – |
-31,131
| Closed | -$4.01M |
|
|
12
Denali Therapeutics
DNLI
$3.65B
| – | – |
-323,749
| Closed | -$25.4M |
|
13
Nurix Therapeutics
NRIX
$2.41B
| – | – |
-154,426
| Closed | -$4.1M |
|
|
14
Snowflake
SNOW
$102B
| – | – |
-47,136
| Closed | -$11.4M |
|
15
Vir Biotechnology
VIR
$1.46B
| – | – |
-25,866
| Closed | -$1.22M |
|
|
CNST
16
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-554,325
| Closed | -$18.7M |
|
Similar funds
WSC
RC
DCM
HBWM
BWM
IPW
TCM
MA
Euclidean Capital's Q3 2021 Portfolio in Review
As of Q3 2021, Euclidean Capital held 16 positions worth $206M, down 33% from $308M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Euclidean Capital withdrew a net $96.1M in Q3 2021, closing 6 positions and reducing 4 holdings. Its most notable exit was Denali Therapeutics, an estimated $25.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Euclidean Capital opened a new position in Tenaya Therapeutics worth $18.9M.
- Euclidean Capital's largest Q3 2021 buy was Tenaya Therapeutics: 915,705 shares worth $18.9M.
- Euclidean Capital added most to Pinduoduo in Q3 2021, an estimated $239K increase.
- Euclidean Capital's biggest Q3 2021 reduction was PMV Pharmaceuticals, cutting an estimated $36.4M.
- Euclidean Capital fully exited Denali Therapeutics in Q3 2021, selling an estimated $25.4M.
- Euclidean Capital's ten largest holdings make up 100% of its $206M portfolio in Q3 2021.
- Euclidean Capital opened 2 new positions and closed 6 in Q3 2021.
- Euclidean Capital's portfolio value fell 33% quarter-over-quarter to $206M.
Based on Euclidean Capital's 13F filing for Q3 2021, filed 15 Nov 2021.